New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
10:00 EDTHES, VNO, NKTR, JCP, CAT, PBR, VRTX, KRC, GRMN, BMY, STRA, JNJ, IQNTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Caterpillar (CAT) downgraded to Neutral from Overweight at JPMorgan... Garmin (GRMN) downgraded to Sell from Neutral at Goldman... Inteliquent (IQNT) downgraded to Underweight from Equal Weight at Morgan Stanley... J.C. Penney (JCP) downgraded to Underperform from Neutral at Credit Suisse... Johnson & Johnson (JNJ) downgraded to Hold from Buy at Jefferies... Kilroy Realty (KRC) downgraded to Neutral from Buy at BofA/Merrill... Nektar (NKTR) downgraded to Hold from Buy at Jefferies... Strayer Education (STRA) downgraded to Neutral from Overweight at JPMorgan... Vertex (VRTX) downgraded to Neutral from Outperform at Credit Suisse... Vornado (VNO) downgraded to Neutral from Buy at BofA/Merrill... Bristol-Meyers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Petrobras (PBR) downgraded to Neutral from Buy at BofA/Merrill... Hess Corp. (HES) downgraded to Market Perform from Outperform at Howard Weil.
News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 22, 2014
18:17 EDTHESOn The Fly: After Hours Movers
Subscribe for More Information
17:23 EDTBMYBristol-Myers confirms FDA approval of Opdivo
Bristol-Myers Squibb Company announced that the FDA approved Opdivo injection, for intravenous use. Opdivo is a human programmed death receptor-1 blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The company expects to begin shipping Opdivo within one to two weeks of today’s approval.
16:33 EDTHESHess Corp. announces LOI with North West Shelf
Subscribe for More Information
15:12 EDTBMYBristol-Myers confirms FDA approval of Opdivo
Subscribe for More Information
14:34 EDTBMYBristol-Myers prices Opdivo at $12.5K per month, CNBC report
Subscribe for More Information
14:28 EDTBMYFDA grants accelerated approval to Bristol-Myers melanoma drug
Subscribe for More Information
10:49 EDTPBRPetrobras CEO gets indication of support from Rousseff, Bloomberg says
Brazilian President Dilma Rousseff indicated support for the current Petrobras CEO Maria das Gracas Foster, saying she does not see any irregularities in the conduct of the current management of the state-controlled oil producer, Bloomberg reported. Shares of Petrobras shares are trading higher bu 1.5% to $7.22 in morning trading. Reference Link
08:01 EDTJNJAASLD publishes new recommendations for treating Hepatitis C
Subscribe for More Information
07:29 EDTGRMNFitness band maker Fitbit plans IPO for next year, Bloomberg reports
Subscribe for More Information
06:39 EDTVRTXHepatitis C deal a blow to biotech bull market, The Street's Feuerstein says
Subscribe for More Information
06:33 EDTJNJSevion announces antibody discovery collaboration with Johnson & Johnson
Subscribe for More Information
06:29 EDTJNJGilead drops 4% after Express Scripts picks AbbVie for hepatitis C
Shares of Gilead (GILD) are moving lower in pre-market trading after Express Scripts (ESRX) spokesman Brian Henry told CNBC's Meg Tirrell and other news outlets that the pharmacy benefits manger will exclusively offer AbbVie's (ABBV) recently approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1. Express Scripts will no longer offer competing drugs from Gilead and Johnson & Johnson (JNJ). Shares of AbbVie are rising 6% to $71.50 in pre-market trading while Gilead is down 4% to $104.15. AbbVie discovered part of the Viekira Pak regimen via its ongoing collaboration with Enanta Pharmaceuticals (ENTA). Shares of Enanta are up 7% to $49.96 in pre-open trading.
06:05 EDTJNJMacroGenics ennters collaboration, license agreement with Janssen
Subscribe for More Information
05:44 EDTJNJExpress Scripts to offer AbbVie hepatitis C drug exclusively, CNBC reports
Express Scripts (ESRX) will offer AbbVie's (ABBV) just approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1, while excluding competing drugs from Gilead (GILD) and Johnson & Johnson (JNJ), CNBC's Meg Tirrell reports, citing comments from the pharmacy benefits manager's spokesman Brian Henry. Reference Link
December 19, 2014
11:08 EDTJNJJohnson & Johnson receives positive CHMP opinion to extend Velcade indication
Subscribe for More Information
09:37 EDTJCPActive equity options trading
Active equity options trading according to Track Data: AAPL TSLA BBRY AMZN CELG GILD JCP AMAT FB
08:56 EDTVNOVornado completes sale of 1740 Broadway for $605M
Subscribe for More Information
06:53 EDTSTRAWhitie House unveils college ratings blueprint, Reuters says
Subscribe for More Information
06:36 EDTCATObama administration to ease many parts of Cuba embargo, NY Times says
Subscribe for More Information
December 18, 2014
16:01 EDTPBROptions Update; December 18, 2014
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use